FB Rice names Melbourne biotech partners
Australian independent IP firm FB Rice has promoted two new Melbourne partners in a bid to strengthen its biotechnology and chemistry practice.
The company has named Dr Patrick McManamny and Dr Marcus Caulfield as its newest partners. Both appointees have been working at FB Rice since 2002.
Dr McManamny is part of the firm’s biotechnology team. He advises clients on patent validity and management issues, focusing on biological drugs such as antibodies and stem cells, as well as diagnostics and drug screening technologies.
Dr Caulfield’s expertise is in organic and polymer chemistry, and he advises companies in both the animal and human health segments.
Both new partners also have clients including universities, hospitals, cooperative research centres and research institutes.
FB Rice was founded over 60 years ago and has been operating in Melbourne for the past 20 years.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
